GH secretagogues
Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV
Falutz J, Allas S, Blot K, et al. · N Engl J Med · 2007
PMID: 18057338 · DOI: 10.1056/NEJMoa072375
Summary
Phase 3 randomized, double-blind, placebo-controlled trial in 412 HIV-infected adults with abdominal fat accumulation; 26 weeks of daily subcutaneous tesamorelin 2 mg vs placebo. Primary endpoint: change in visceral adipose tissue by CT.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →TesamorelinStabilized GHRH analog studied in lipodystrophy and visceral-adiposity research models.
Guides covering this compound
- Sermorelin — GHRH (1-29) and the peptide family built on itSermorelin is the unmodified first 29 residues of growth hormone releasing hormone. Every GHRH analog in this market is a modification of it.2 min read
- Freeze-thaw cycles and peptide integrityFreezing a peptide solution is not free. Each cycle concentrates solutes, shifts pH, and creates ice interfaces — which is why aliquoting beats re-freezing.3 min read
- Cold chain and ambient shipping — what actually survives transitLyophilized peptides ship ambient for good reason. Here is the science behind that, and what would genuinely warrant a cold pack.3 min read
- CJC-1295 vs Ipamorelin: two different receptorsThe most-compared pair in endocrine research supply act on different receptor families entirely. What that means, plus the 4.7× mass gap and the DAC question.6 min read
More GH secretagogues citations
- Ipamorelin, the first selective growth hormone secretagogueEur J Endocrinol · 1998
- Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in ratsGrowth Horm IGF Res · 1999
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsJ Clin Endocrinol Metab · 2006